White Paper: Advanced Flow Cytometry – Rapid Analysis for Complex Cell-Based Models
The growing recognition that pre-clinical animal models often provide incomplete or erroneous results, potentially leading to costly late-stage failures for new drug candidates has opened avenues for the use of cell-based assays that more accurately predict the in vivo activity of new therapeutic agents as a practical alternative. Additionally, advances in our understanding of cell biology and the shift from universally applicable small molecule drugs towards precision medicine approaches and biotherapeutics have resulted in a move towards the use of cell-based assays far earlier in the drug discovery workflow.
Traditional cell-based approaches are, however, not designed to handle the far larger sample sets and high throughput screening assays commonly required for early-stage candidate identification.
Download this white paper to learn how advanced flow cytometry addresses these challenges to deal with the demands of modern drug discovery pipelines.
